Stonegate Investment Group LLC lifted its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 2.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,199 shares of the conglomerate's stock after acquiring an additional 4,830 shares during the quarter. Danaher accounts for about 1.4% of Stonegate Investment Group LLC's holdings, making the stock its 28th biggest position. Stonegate Investment Group LLC's holdings in Danaher were worth $51,694,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the company. Wedge Capital Management L L P NC lifted its stake in Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate's stock valued at $342,000 after buying an additional 38 shares in the last quarter. Meridian Financial Partners LLC lifted its position in shares of Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate's stock valued at $266,000 after acquiring an additional 40 shares in the last quarter. Kovack Advisors Inc. boosted its stake in shares of Danaher by 3.4% during the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate's stock valued at $346,000 after acquiring an additional 41 shares during the last quarter. Well Done LLC increased its position in Danaher by 1.2% during the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate's stock worth $987,000 after purchasing an additional 42 shares in the last quarter. Finally, Waypoint Capital Advisors LLC raised its stake in Danaher by 0.9% in the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate's stock valued at $1,257,000 after purchasing an additional 42 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.
Danaher Price Performance
DHR stock traded down $2.82 during trading on Tuesday, hitting $247.77. The company had a trading volume of 4,273,052 shares, compared to its average volume of 2,989,633. The business has a 50 day moving average of $235.75 and a 200 day moving average of $253.65. The firm has a market capitalization of $178.96 billion, a price-to-earnings ratio of 47.29, a P/E/G ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a fifty-two week low of $225.42 and a fifty-two week high of $281.70.
Danaher Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher's dividend payout ratio is currently 20.61%.
Wall Street Analysts Forecast Growth
DHR has been the topic of several analyst reports. TD Cowen raised their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a research note on Wednesday, October 23rd. Stephens reaffirmed an "overweight" rating and issued a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Evercore ISI increased their price target on Danaher from $275.00 to $278.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. Robert W. Baird lowered their price objective on Danaher from $277.00 to $268.00 and set an "overweight" rating for the company in a research report on Tuesday. Finally, Scotiabank started coverage on Danaher in a research report on Monday, December 23rd. They set a "sector perform" rating and a $265.00 target price on the stock. Six research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Danaher presently has an average rating of "Moderate Buy" and a consensus target price of $285.81.
View Our Latest Stock Report on Danaher
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
